Eaton Vance Management’s Allogene Therapeutics ALLO Stock Holding History

Eaton Vance Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.56M	Hold	237,155	–	–	﹤0.01%	978
2022 Q2	$2.7M	Hold	237,155	–	–	﹤0.01%	984
2022 Q1	$2.16M	Hold	237,155	–	–	﹤0.01%	1156
2021 Q4	$3.54M	Hold	237,155	–	–	﹤0.01%	875
2021 Q3	$6.09M	Hold	237,155	–	–	0.01%	677
2021 Q2	$6.18M	Sell	237,155 -198	-0.1%	-$5.65K	0.01%	719
2021 Q1	$8.38M	Buy	237,353 +198	+0.1%	+$6.68K	0.01%	599
2020 Q4	$5.99M	Hold	237,155	–	–	0.01%	654
2020 Q3	$8.94M	Hold	237,155	–	–	0.02%	502
2020 Q2	$10.2M	Hold	237,155	–	–	0.02%	452
2020 Q1	$4.61M	Buy	+237,155	New	+$5.65M	0.01%	563

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eaton Vance Management's ALLO Position: Q3 2022 in Review

Eaton Vance Management held its Allogene Therapeutics (ALLO) position steady in Q3 2022 at 237,155 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Eaton Vance Management first reported a position in ALLO in Q1 2020 and has held it in 11 quarters since. The position peaked at $10.2M in Q2 2020. 192 funds tracked by Wall St. Rank hold ALLO as of Q3 2022.

Eaton Vance Management held 237,155 shares of Allogene Therapeutics worth $2.56M as of Q3 2022.
Eaton Vance Management left its Allogene Therapeutics share count unchanged in Q3 2022.
Allogene Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #978 holding.
Eaton Vance Management first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 11 quarters since.
Eaton Vance Management's Allogene Therapeutics position peaked at $10.2M in Q2 2020.
192 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.